1. Home
  2. VERU vs NSAI Comparison

VERU vs NSAI Comparison

Compare VERU & NSAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veru Inc.

VERU

Veru Inc.

SELL

Current Price

$2.09

Market Cap

41.9M

Sector

Health Care

ML Signal

SELL

NSAI

NorthStrive Acquisition Corp I. Class A Ordinary Shares

N/A

Current Price

$9.94

Market Cap

47.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
VERU
NSAI
Founded
1971
2026
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.9M
47.9M
IPO Year
1996
2026

Fundamental Metrics

Financial Performance
Metric
VERU
NSAI
Price
$2.09
$9.94
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $25.67
N/A
AVG Volume (30 Days)
★ 106.8K
45.8K
Earning Date
12-16-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $16,296,958.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$2.04
$9.82
52 Week High
$7.33
$10.00

Technical Indicators

Market Signals
Indicator
VERU
NSAI
Relative Strength Index (RSI) 40.86 55.70
Support Level $2.09 $9.82
Resistance Level $2.68 $9.94
Average True Range (ATR) 0.11 0.02
MACD 0.00 0.01
Stochastic Oscillator 26.67 45.45

Price Performance

Historical Comparison
VERU
NSAI

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

About NSAI NorthStrive Acquisition Corp I. Class A Ordinary Shares

NorthStrive Acquisition Corp I is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.

Share on Social Networks: